Skip to main content
. 2005 Feb 7;102(7):2490–2495. doi: 10.1073/pnas.0409883102

Table 1. Tumor incidence and tumor invasion area within reproductive tracts.

Treated 9 months with estrogen
Treated first 6 of 9 months with estrogen
Genotype No. of mice with cancer* (%) Avg. no. of cancers per mouse Total area of tumor invasion per mouse, mm2 Largest area of tumor invasion per mouse, mm2 No. of mice with cancer* (%) Avg. no. of cancers per mouse Total area of tumor invasion per mouse, mm2 Largest area of tumor invasion per mouse, mm2
Nontransgenic 1/15 (6) 0.067 ± 0.26 0.029 ± 0.11 0.029 ± 0.11 0/12 (0)
K14E7 11/11 (100) 6.6 ± 3.6 18 ± 13 13 ± 11 5/18 (38) 0.54 ± 0.78 2.1 ± 3.6 2.0 ± 3.4
K14E6/K14E7 6/6 (100) 7.0 ± 2.9 49 ± 26 37 ± 21 9/11 (82) 1.3 ± 0.79 6.3 ± 7.9 5.0 ± 6.4
*

Denominators are number of mice that survived to the end of 9 months. Morbidity was caused by estrogen-induced bladder distension (9), spontaneous squamous cell carcinoma of the skin (8), and thymic hyperplasia (37)